Does CYTEK BIOSCIENCES, INC. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores CYTEK BIOSCIENCES, INC. (CTKB) 43.4 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 90, returns on capital 7, balance-sheet safety 28, capital discipline 44.

How has CTKB's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 43.4 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

CYTEK BIOSCIENCES, INC.

CTKB · Healthcare · $593.9M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power90

Median gross margin 56.2% over 6y, very stable.

Returns on capital7

Median ROIC -5.5%, above the 9% hurdle in 20% of years.

Balance-sheet safety28

Net debt/EBITDA n/ax, interest coverage -85x.

Capital discipline44

Owner earnings trend unclear, share count n/a.

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $4.62
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for CTKB yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale43.4 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — CTKB has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#199 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#197XBIT XBIOTECH INC.43.4 out of 100, Shallow moatShallow moat
#198VRCA Verrica Pharmaceuticals Inc.43.4 out of 100, Shallow moatShallow moat
#200CDNA CAREDX, INC.43.2 out of 100, Shallow moatShallow moat
#201LCTX Lineage Cell Therapeutics, Inc.43.1 out of 100, Shallow moatShallow moat

Compare CTKB with its nearest peers →All Healthcare companies on the Index →

Common questions about CTKB

Does CYTEK BIOSCIENCES, INC. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores CYTEK BIOSCIENCES, INC. (CTKB) 43.4 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 90, returns on capital 7, balance-sheet safety 28, capital discipline 44.
How has CTKB's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 43.4 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows CTKB’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/CTKB"
  width="340" height="150" style="border:0"
  title="CTKB Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell CTKB. See the disclaimer.